{
    "clinical_study": {
        "@rank": "132877", 
        "arm_group": [
            {
                "arm_group_label": "radiofrequency-assisted resection group\uff08RF-R)", 
                "arm_group_type": "Experimental", 
                "description": "Radiofrequency-assisted resection: separating the tumor from liver by using the probe of radiofrequency to block the arterial and vessels before parenchymal transection."
            }, 
            {
                "arm_group_label": "conventional liver resection group\uff08CLR-R\uff09", 
                "arm_group_type": "Active Comparator", 
                "description": "Conventional liver resection group: hepatectomy only without RF assisted during parenchymal transection.Separating and dissecting the tumor with the routine clamp-crushing technical."
            }
        ], 
        "brief_summary": {
            "textblock": "Surgical resection is the most effective treatment of primary and secondary liver tumors.\n      Technical innovations have mainly focused on minimizing bleeding during transection of the\n      hepatic parenchyma because excessive hemorrhage and the need for blood transfusion are\n      associated with increased postoperative morbidity and mortality.\n      Recently,radiofrequency-assisted\uff08RFA\uff09hepatectomy has developed rapidly and gained widespread\n      acceptance for the treatment of hepatocellular carcinomas\uff08HCC\uff09\uff0cbut its influence on the\n      prognosis of HCC patients\uff0cespecially for those with cirrhosis\uff0cis still controversial.\n      Therefore, we design this prospective clinical trial to explore the effect of RFA\n      hepatectomy versus the conventional hepatectomy on the outcomes of perioperative period and\n      prognosis of HCC patients with cirrhosis."
        }, 
        "brief_title": "Radiofrequency-assisted Hepatectomy on the Outcomes of HCC Patients With Cirrhosis", 
        "completion_date": {
            "#text": "November 2018", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hepatocellular Carcinoma", 
            "Cirrhosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Liver Cirrhosis", 
                "Fibrosis", 
                "Carcinoma, Hepatocellular"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Aged from 18 to 65 years , no gender restriction.\n\n          -  Clinical diagnosis of resectable HCC.\n\n          -  Preoperative liver function test showed Child-Pugh Class A or B.\n\n          -  Indocyanine green retention at 15 minutes (ICG-15) of <30%.\n\n          -  Acceptable clotting profile :platelet count  \uff1e 50 x 109/L and a prolonged prothrombin\n             time of < 5 seconds.\n\n          -  Enough relative residual liver volume (%RLV)  \u2265 40%.\n\n          -  No tumor invasion in primary branch of portal vein, hepatic vein, or inferior vena\n             cava.\n\n          -  No other anti-tumor therapy received before the treatment.\n\n          -  No metastasis in lymphnode or other organs.\n\n          -  Written consent inform assigned.\n\n        Exclusion Criteria:\n\n          -  Pregnancy.\n\n          -  Intraoperative findings of tumor rupture\uff0cextrahepatic tumor or lymphnode metastasis.\n\n          -  Tumor invasion in primary branch of portal vein, hepatic vein, or inferior vena cava."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01992978", 
            "org_study_id": "SWHB2013-005"
        }, 
        "intervention": [
            {
                "arm_group_label": "radiofrequency-assisted resection group\uff08RF-R)", 
                "description": "Radiofrequency-assisted resection: separating the tumor from liver by using the probe of radiofrequency to block the arterial and vessels before parenchymal transection.", 
                "intervention_name": "Radiofrequency-assisted Hepatectomy", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "conventional liver resection group\uff08CLR-R\uff09", 
                "description": "Hepatectomy was conducted  without RF assisted during parenchymal transection. Separating and dissecting the tumor with the routine clamp-crushing technical.", 
                "intervention_name": "Conventional  Hepatectomy", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "radiofrequency-assisted\uff08RF\uff09", 
            "hepatectomy", 
            "postoperative liver injury"
        ], 
        "lastchanged_date": "November 26, 2013", 
        "location": {
            "contact": {
                "email": "ruixx032@163.com", 
                "last_name": "Rui Guo, Master of Medicine", 
                "phone": "86-23-15922654727"
            }, 
            "facility": {
                "address": {
                    "city": "Chongqing", 
                    "country": "China", 
                    "state": "Chongqing", 
                    "zip": "400038"
                }, 
                "name": "Institute of Hepatobiliry surgery,Southwest Hospital"
            }, 
            "investigator": {
                "last_name": "Xiaowu Li, MD-Ph D", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Influence of Radiofrequency-assisted Hepatectomy on the Perioperative Outcomes and the Long-term Prognosis of HCC With Cirrhosis\uff1aA Prospective Randomized Controlled Trial", 
        "other_outcome": {
            "description": "Blood parameter change after operation is measured by postoperative blood routine test till the hospitalization. The estimated average postoperative hospitalization ranges from 10 ot 15 days (generally 2 weeks). If the incidence of postoperative hepatic insufficiency occurred beyond hospitalization,blood routine test is also necessarily counted in.", 
            "measure": "Blood parameter change after operation", 
            "safety_issue": "Yes", 
            "time_frame": "discharge from hospital (2 weeks)"
        }, 
        "overall_contact": {
            "email": "ruixx032@163.com", 
            "last_name": "Rui Guo, Master of Medicine", 
            "phone": "86-23-15922654727"
        }, 
        "overall_contact_backup": {
            "email": "guor2006@gmail.com", 
            "last_name": "Li Liu, MD", 
            "phone": "86-23-68754374"
        }, 
        "overall_official": {
            "affiliation": "Institute of hepatobiliry surgery,Southwest hospital", 
            "last_name": "Xiaowu Li, MD-Ph D", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The degree of postoperative hepatic injury is assessed by daily measurements of postoperative aminotransferase (AST) and alanine aminotransferase (ALT) levels, serum bilirubin levels, and prothrombin times. Each patient is followed up within postoperative 90 days.", 
            "measure": "Postoperative liver injury", 
            "safety_issue": "Yes", 
            "time_frame": "postoperative 90 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01992978"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Southwest Hospital, China", 
            "investigator_full_name": "Li Xiaowu,MD", 
            "investigator_title": "Dr.Xiaowu Li", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "It is evaluated according to the the Clavien-Dindo Classification of surgical complications. Postoperative mortality and morbidity are measured.", 
                "measure": "Number of Participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "postoperative 90 days"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "1,3,5-year overall survival"
            }
        ], 
        "source": "Southwest Hospital, China", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Southwest Hospital, China", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}